Abstract 900P
Background
We aimed to study the effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections on patients with head and neck malignancies and evaluate the efficacy of vaccination.
Methods
The Head and Neck cancERs international cOviD-19collabOraTion (HERODOTUS) registry is a multicentre observational study comprised of a retrospective component and a prospective cohort component. Eligibility criteria were the presence of any head and neck cancer (including salivary gland, thyroid, nasal and paranasal cancer) and a COVID-19 diagnosis. Clinical data were extracted from medical records of consecutive patients from November 1, 2019 until September 30, 2022. Associations between demographic or clinical characteristics and outcomes were measured by odds ratios (ORs) with 95% CIs using univariable and multivariable logistic regression; sex, age, smoking status, and HPV status (for oropharynx cancer) were the covariates included in the multivariable analysis. End points include mortality, hospitalization, symptomatic COVID-19 infection, asymptomatic COVID-19 infection, and delay in cancer therapy.
Results
395 COVID-19+ head and neck cancers were identified, out of which, there were 76 deaths. Univariable analyses revealed that age >63 years (OR 3.4, CI 1.9-5.9)); being a current or former smoker (OR: 2, CI: 1.1-2.8), having comorbidities (OR: 2.4, CI: 1.2-5), having a history of COPD (OR: 3.6, CI: 1.7-8), having squamous cell carcinoma (HNSCC) (OR: 4.3, CI: 1.8-10.2), or receiving treatment with chemotherapy and cetuximab (OR: 3.8, CI: 1.4-10.5) were associated with increased risk of death, whereas vaccination was protective (OR: 0.20,CI: 0.11 – 0.34). On multivariable analysis, age>63 yo (OR: 2.3, CI: 1.0-5.2), COPD (OR: 4.9, CI: 1.8-13.8), and chemotherapy with cetuximab (OR: 6.1, CI: 1.9-20) were associated with increased risk of death. Non-vaccinated HNSCC pts had an OR for death of 27.7 (CI: 6.2-122).
Conclusions
This is the largest, to our knowledge, cohort of patients with Head and Neck Cancer and COVID-19. The data show the negative impact of age, COPD and the chemotherapy plus cetuximab regimens on survival while vaccination was protective.
Clinical trial identification
NCT04632173.
Editorial acknowledgement
Legal entity responsible for the study
Hellenic Cooperative Oncology Group.
Funding
Hellenic Cooperative Oncology Group.
Disclosure
A. Psyrri: Financial Interests, Personal, Invited Speaker: MSD, Merck Serono; Financial Interests, Personal, Advisory Board: Pfizer, Sanofi, MSD, AstraZeneca, BMS, LEO, RAKUTEN, eTheRNA immunotherapies, Merck Serono; Financial Interests, Personal and Institutional, Local PI: AstraZeneca, Pfizer, GSK, GENESIS, Incyte, Amgen, Debiopharm, MSD, Jannsen, Lilly, Regeneron, Sanofi, BI, Roche, Peregrine, Oncolytics Biotech; Financial Interests, Coordinating PI: AstraZeneca; Financial Interests, Personal and Institutional, Steering Committee Member: Iovance, Pfizer, Roche; Financial Interests, Institutional, Steering Committee Member: KURA ONCOLOGY; Financial Interests, Steering Committee Member: KURA ONCOLOGY; Financial Interests, Personal and Institutional, Funding: KURA ONCOLOGY, BMS, Roche, DEMO, Amgen, BI, GENESIS, BMS, Pfizer, Oncolytics Biotech; Financial Interests, Institutional, Funding: Merck Serono, Pfizer; Financial Interests, Personal, Other, Educational activity: MEDSCAPE, PrimeOncology; Financial Interests, Institutional, Local PI: Novartis, Replimmune; Non-Financial Interests, Project Lead, Medical Education with honoraria: MEDSCAPE. R. Mesia Nin: Financial Interests, Personal, Advisory Board: Merck, MSD, Bayer, Seattle Genetics, Nanobiotix, Boehringer, Segean; Financial Interests, Personal, Invited Speaker: Merck, MSD, BMS; Non-Financial Interests, Principal Investigator, Clinical Trial PI: BMS; Non-Financial Interests, Principal Investigator, Observational trial PI: Merck. L.F.L. Licitra: Financial Interests, Personal, Advisory Board, for expert opinion in advisory boards: AstraZeneca, Bayer, BMS, Eisai, MSD, Merck–Serono, Boehringer Ingelheim, Hoffmann-La Roche Ltd, Novartis, Roche, Debiopharm International SA, Sobi, Incyte Biosciences Italy srl, Doxa Pharma srl, Amgen, Nanobiotics e GSK.; Financial Interests, Institutional, Research Grant, Funds received by my institution for clinical studies and research activities in which I am involved: AstraZeneca, BMS, Boehringer Ingelheim, Celgene International, Eisai, Exelixis, Debiopharm International SA, Hoffmann-La Roche ltd, IRX Therapeutics, Medpace, Merck–Serono, Merck Healthcare KGaA, MSD, Novartis, Pfizer, Roche, Buran.. All other authors have declared no conflicts of interest.
Resources from the same session
899P - Impact of COVID-19 pandemic on treatment and survival in head and neck squamous cell carcinoma (HNSCC) patients (IMPACCT Study)
Presenter: Berta Vilar Anglada
Session: Poster session 12
901P - Gut microbiome metagenomics and toxicity outcomes from chemoradiation therapy in head and neck squamous cell carcinoma
Presenter: Antoine Desilets
Session: Poster session 12
902P - Cisplatin-induced ototoxicity in head and neck cancer: The patterns and prediction
Presenter: Chiaki Suzuki
Session: Poster session 12
903P - AL101 therapy in patients with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC): Final ACCURACY trial results and meta-analysis of clinical outcomes
Presenter: Renata Ferrarotto
Session: Poster session 12
904P - Retrospective analysis of adjuvant systemic anti-hormonal therapy for resected androgen receptor-positive (AR+) salivary duct carcinoma (SDC)
Presenter: Jetty Weijers
Session: Poster session 12
905P - Hot topics in salivary gland carcinomas treatment: An EORTC young investigator and early career investigator survey
Presenter: Luigi Lorini
Session: Poster session 12
906P - Multi-parameter flow cytometry analysis of circulating immune cell populations in recurrent/metastatic adenoid cystic carcinoma
Presenter: Samuel Rack
Session: Poster session 12
907P - Radiosensitivity signature in adenoid cystic carcinoma (ACC) of salivary glands origin is associated with ACC type II
Presenter: Laura Locati
Session: Poster session 12
908P - Efficacy of NOTCH inhibitors (Ni) relative to prior systemic therapy or observation in patients (pts) with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC)
Presenter: Camilla Hoff
Session: Poster session 12
909P - TROP2 expression in salivary gland adenoid cystic carcinoma (ACC): A new potential therapeutic target for the non-solid subtype
Presenter: Juliana Mota Siqueira
Session: Poster session 12